Evidence map›Paper›PMID 40123635›Full record

ArticleIndian journal of clinical biochemistry : IJCB2025

Exon Sequence Analysis of the

Tuğba Mehmetoğlu Gürbüz, Ethem Nezih Oral, Rabia Nergiz Dağoğlu Sakin, Şule Karaman, Şermin Durak, Saadet Büşra Aksoyer Sezgin, Metin Keskin, Faruk Çelik, Ş Ümit Zeybek

Abstract read
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tuğba Mehmetoğlu GürbüzAziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul University, Topkapi, Gureba Hospital Street, Number: 69, 34093 Fatih/Istanbul, Turkey.ORCID 0000-0003-1417-9446
Ethem Nezih OralInstitute of Oncology, Department of Radiation Oncology, Istanbul University, Istanbul, Turkey.ORCID 0000-0002-4370-7386
Rabia Nergiz Dağoğlu SakinInstitute of Oncology, Department of Radiation Oncology, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-3925-3382
Şule KaramanInstitute of Oncology, Diagnostic Treatment and Care Services, Istanbul University, Istanbul, Turkey.ORCID 0000-0002-4810-4453
Şermin DurakAziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul University, Topkapi, Gureba Hospital Street, Number: 69, 34093 Fatih/Istanbul, Turkey.ORCID 0000-0001-6741-4345
Saadet Büşra Aksoyer SezginMedical Faculty, Department of Medical Biology, Istanbul Yeni Yüzyıl University, Istanbul, Turkey.ORCID 0000-0002-8338-9546
Metin KeskinIstanbul Faculty of Medicine, Department of General Surgery, Istanbul, Turkey.ORCID 0000-0002-5390-2185
Faruk ÇelikAziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul University, Topkapi, Gureba Hospital Street, Number: 69, 34093 Fatih/Istanbul, Turkey.ORCID 0000-0003-2433-0277
Ş Ümit ZeybekAziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul University, Topkapi, Gureba Hospital Street, Number: 69, 34093 Fatih/Istanbul, Turkey.ORCID 0000-0001-8403-2939

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy (RT) which is a treatment regime for cancer patients may cause genetic instability and side effects. Etiological associations exist amongst autophagy-related gene (ATG) mutation and cancer. RT increases the rate of autophagy previously proven in vitro. The aforementioned background diverted us to conduct exon mutation analysis for ATG5, ATG12, and ATG9B genes of colorectal cancer patients who were receiving neoadjuvant RT. Peripheral blood DNA from different time points (before/middle/after RT) of the same patients was isolated and most tandem repeat-containing exons of ATG5, ATG12, and ATG9B were polymerase chain reaction-amplified and examined for mutations by Sanger sequencing. CA19-9/CEA (Tumor marker of colorectal cancer/Carcinoembryonic Antigen) serum levels were retrieved from the clinic. No exon variations detected for ATG5 and ATG12 genes. However, 4 patients (17.4%) showed frameshift mutation for ATG9B gene. Exon variation analysis of 2 (8.7%) patients resulted in GGG deletion at 8G mononucleotide tandem repeat region of ATG9B. Assigning patients as before RT and after RT, CA19-9 levels in ATG9B (Mutation) patients were higher compared to ATG9B (Wild Type) patients. ATG9B is highly likely to mutate during RT and ATG9B mutation correlates to higher CEA and CA19-9 levels and patients show poor prognosis. Supplementary Information: The online version contains supplementary material available at 10.1007/s12291-023-01177-6.

Indexed as

ATG9BAutophagyMutation analysisRadiotherapy

Identifiers

PMID40123635
PMCPMC11928699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.